1. Home
  2. NDRA vs IMRN Comparison

NDRA vs IMRN Comparison

Compare NDRA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

SELL

Current Price

$4.97

Market Cap

8.2M

Sector

Health Care

ML Signal

SELL

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.00

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDRA
IMRN
Founded
2007
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
9.4M
IPO Year
2016
2016

Fundamental Metrics

Financial Performance
Metric
NDRA
IMRN
Price
$4.97
$1.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.1K
★ 61.5K
Earning Date
11-16-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.32
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$16.39
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$0.68
52 Week High
$6.95
$2.35

Technical Indicators

Market Signals
Indicator
NDRA
IMRN
Relative Strength Index (RSI) 39.60 33.93
Support Level $4.87 $0.77
Resistance Level $4.90 $1.00
Average True Range (ATR) 0.36 0.06
MACD -0.16 -0.01
Stochastic Oscillator 9.73 8.45

Price Performance

Historical Comparison
NDRA
IMRN

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: